Ultragenyx Pharma Q2 Loss Narrows; Lifts FY Revenue Guidance; Stock Up In After-hours
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Ultragenyx Pharmaceutical Inc. (RARE) reported that its second quarter net loss narrowed to $131.60 million or $1.52 per share from $159.83 million or $2.25 per share in the prior year.
:max_bytes(150000):strip_icc():format(jpeg)/FlyFirstClassforCheap-d3852e14d3984fddb9a46fcb17fc93c2.jpg "How to Fly First Class for Cheap")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-506997606-3aeda39d7c734e459725400f855c816d.jpg "Is Shopping at Big-Box Stores Worth It? Factors to Consider")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1169041231-5052d200552d467baab33417938984a3.jpg "10 Low-Risk Income Sources for a Safer Retirement")
